Study analysis · bioRxiv · 2025
Adrenal cancer may have an Achilles' heel: an addiction to glutamine—and blocking it shrank tumors by over 80% in mice (relative tumor-growth inhibition, not a human cure).
In mice with adrenocortical carcinoma, glutamine-blocking drugs slowed tumor growth by more than 80% relative to vehicle and prolonged survival, but it is not yet known if they help people.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study mixes lab experiments in cells and mice with a comparison of blood samples from people with a rare cancer versus benign tumors. It shows that the cancer cells rely on glutamine and that blocking it shrinks tumors in mice, but it does not prove that the same treatment works or is safe in people.
What’s the bottom line?
Adrenocortical carcinoma cells seem to need glutamine to make nucleotides. Drugs that block glutamine use slowed cancer cells and mouse tumors, and combining one drug with a DNA-damage-response inhibitor worked even better.
How strong is this study?
The study uses many different methods and checks the same idea in mice and human samples, which makes the lab findings more convincing. But it is not a human clinical trial, so we cannot be sure the treatment will help patients, and the human part only looks at existing samples rather than testing the drug.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
44 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 549 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. The human component is an observational case-control serum metabolomics comparison (ACC vs benign adrenocortical adenomas), not a randomized clinical trial. It cannot establish that glutamine metabolism causes ACC or that glutamine antagonism treats ACC in humans. Preclinical in vitro and mouse in vivo experiments can support mechanistic hypotheses but do not prove human efficacy or safety.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information is disclosed in the provided text; potential author ties to JHU-083 are not explicitly stated.
The provided excerpt lacks a conflict of interest or funding section. JHU-083 is a Johns Hopkins-developed prodrug, which may imply author affiliations or patents, but no disclosure is present in the text.
Key takeaways
- 01
In mice with ACC tumors, JHU-083 reduced tumor growth by more than 80% relative to vehicle after 9 days and prolonged survival.
- 02
In ACC cells, DON stopped growth at low concentrations (IC50 0.03–4.07 µM).
- 03
In human ACC serum, 437 metabolites differed from benign tumors, and glutamine was lower.
- 04
High expression of four glutamine-related nucleotide enzymes was linked to worse survival (relative association; absolute risk not reported).
- 05
This is preclinical and early human metabolomic evidence.
- 06
The >80% is relative tumor-growth inhibition in mice, not an absolute human survival benefit.
- 07
No absolute risk increase or decrease for patients was reported.
- 08
The human data are associations only, so it is not proven that blocking glutamine improves survival in people.
Surprising findings
- Nucleosides alone completely rescued cancer cells from a glutamine blocker.Glutamine feeds many pathways; finding that nucleotide rescue fully reverses toxicity suggests nucleotide synthesis is the dominant dependency.
- The drug worked even in immunodeficient mice.Some glutamine antagonists rely on immune activation; this suggests ACC response is largely immune-independent.
- Blocking a metabolic enzyme caused DNA damage.Metabolism and DNA repair are often seen as separate; here nucleotide depletion led to replication stress and γH2AX increase.
- Human serum glutamine was depleted, not elevated.If tumors consume glutamine, blood levels may drop, which is counterintuitive for a nutrient cancer needs.
Practical takeaways
Do not take glutamine-blocking drugs or restrict glutamine based on this study.
No human efficacy data; DON historically toxic; self-experimentation is dangerous.
high confidencePatients with ACC can ask their oncologist about clinical trials of glutamine antagonists such as DRP-104 or ATR inhibitors.
No approved regimen; trial eligibility and risks unknown.
medium confidenceResearchers and clinicians should consider p53 status and nucleotide biosynthesis gene expression in future trials.
Biomarker validation is still needed.
medium-low confidenceContent creators should frame over 80% as relative tumor-growth inhibition in mice, not a human cure.
Absolute human benefit was not reported.
high confidenceWhy this study matters
A rare cancer's metabolic addiction
Cross-species RNA-seq found 68% overlap in upregulated metabolic pathways between human and mouse ACC, including glutamine-dependent nucleotide biosynthesis, hexosamine biosynthesis, and glutathione metabolism. That suggests ACC tumors are rewired to depend on glutamine.
ACC is rare and aggressive with median survival under 15 months in metastatic disease and no effective targeted treatments.
Dramatic mouse results—with a catch
The glutamine antagonist DON and its prodrug JHU-083 inhibited ACC cell viability with IC50 0.03–4.07 µM. In a mouse syngeneic implant model, JHU-083 produced over 80% relative tumor-growth inhibition after 9 days and prolonged survival; it also worked in human ACC xenografts.
Shrinking tumors by over 80% in mice sounds like a breakthrough, but relative inhibition is not an absolute human survival benefit.
The mechanism: DNA building blocks, not just energy
Nucleoside supplementation fully rescued cell viability in all four ACC cell lines after DON, while non-essential amino acids, GlcNAc, αKG, or antioxidants failed. This pinpoints glutamine-fueled de novo nucleotide biosynthesis as the main killer pathway.
It overturns the idea that glutamine mainly fuels energy; here it is about making DNA and RNA building blocks.
A synergistic combo: glutamine blockade plus ATR inhibitor
JHU-083 caused DNA double-strand breaks (increased γH2AX) in mouse and human xenograft tumors. Combining DON with ATR inhibitor elimusertib produced synergistic apoptosis, especially in p53-deficient ACC cell lines.
It suggests a rational drug combination that could target aggressive, p53-mutant cancers.
Blood clues in patients
Untargeted serum metabolomics in 54 ACC versus 291 age- and BMI-matched benign adenoma patients found 437 differentially abundant metabolites (FDR under 0.05), with depleted circulating glutamine and increased nucleotide salvage and degradation metabolites.
A simple blood test might one day help distinguish ACC from benign adrenal tumors or reveal metabolic vulnerability.
Four genes linked to worse survival
High expression of PFAS, GMPS, CAD, and CTPS1—four of five key glutamine-dependent de novo nucleotide enzymes—was significantly associated with worse overall survival in TCGA ACC. Only 5 of 32 other cancers showed comparable patterns.
These could become biomarkers for who might respond to glutamine antagonists.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Adrenocortical carcinoma cells seem to need glutamine to make nucleotides. Drugs that block glutamine use slowed cancer cells and mouse tumors, and combining one drug with a DNA-damage-response inhibitor worked even better.
Research results
In mice with ACC tumors, JHU-083 reduced tumor growth by more than 80% relative to vehicle after 9 days and prolonged survival. In ACC cells, DON stopped growth at low concentrations (IC50 0.03–4.07 µM). In human ACC serum, 437 metabolites differed from benign tumors, and glutamine was lower. High expression of four glutamine-related nucleotide enzymes was linked to worse survival (relative association; absolute risk not reported).
What this means - more context
This is preclinical and early human metabolomic evidence. The >80% is relative tumor-growth inhibition in mice, not an absolute human survival benefit. No absolute risk increase or decrease for patients was reported. The human data are associations only, so it is not proven that blocking glutamine improves survival in people.
Preclinical and human metabolomic study asking whether adrenocortical carcinoma (ACC) depends on glutamine metabolism and whether glutamine antagonists can suppress tumor growth.
Cross-species multi-omic analysis found conserved glutamine-dependent metabolic rewiring in ACC. Glutamine antagonists DON/JHU-083 inhibited ACC cell viability (IC50 0.03–4.07 µM) and produced >80% relative tumor-growth inhibition after 9 days in a mouse syngeneic implant model, with prolonged survival. The effect was primarily mediated by blocking glutamine-fueled de novo nucleotide biosynthesis and was rescued by nucleosides. DON induced DNA damage and synergized with ATR inhibitor elimusertib. High expression of four glutamine-metabolizing nucleotide enzymes was associated with worse overall survival, and serum metabolomics showed 437 differentially abundant metabolites (FDR<0.05) with depleted circulating glutamine. Absolute human risk reductions were not reported.
Methods Used
Integrated human/mouse ACC RNA-seq, targeted tissue metabolomics in a mouse ACC model, untargeted serum metabolomics in 54 ACC vs 291 age/BMI-matched benign adrenocortical adenoma patients, ACC cell lines, randomized mouse syngeneic/xenograft treatment with JHU-083 vs vehicle, rescue and synergy assays, and TCGA survival analysis.
Main Finding
Glutamine antagonism suppresses ACC growth in preclinical models: >80% relative inhibition of tumor growth after 9 days in mice and IC50 0.03–4.07 µM in ACC cell lines. Mechanistically, DON acts mainly through inhibition of de novo nucleotide biosynthesis, with nucleoside rescue. High expression of PFAS, GMPS, CAD, and CTPS1 was associated with worse overall survival; the absolute survival risk difference was not reported.
Confidence Level
Moderate—robust cross-species preclinical and human metabolomic data support glutamine dependency, but this is not a clinical efficacy study; preprint, no blinding, no metabolic tracing, and absolute human risk/benefit are not reported.
Study Flags
Red Flags
- •Preclinical models with no clinical efficacy endpoints
- •Human serum metabolomics is observational and cannot establish causation
- •No metabolic tracing to directly quantify glutamine fate; no blinding; preprint not peer-reviewed
Surprising Findings
Nucleosides alone completely rescued cancer cells from a glutamine blocker.
Glutamine feeds many pathways; finding that nucleotide rescue fully reverses toxicity suggests nucleotide synthesis is the dominant dependency.
Practical Takeaways
Do not take glutamine-blocking drugs or restrict glutamine based on this study.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 549 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study mixes lab experiments in cells and mice with a comparison of blood samples from people with a rare cancer versus benign tumors. It shows that the cancer cells rely on glutamine and that blocking it shrinks tumors in mice, but it does not prove that the same treatment works or is safe in people.
Strengths
- Cross-species integration of human and mouse transcriptomic and metabolomic data.
- Use of multiple ACC cell lines including a new murine line and human lines with common driver alterations.
- In vivo evaluation in syngeneic and xenograft mouse models with randomized treatment allocation.
Weaknesses
- No randomized controlled trial in humans; clinical efficacy remains unproven.
- No blinding in animal experiments or outcome assessment, increasing risk of performance and detection bias.
- Small sample sizes in some mouse experiments and limited details on randomization methods.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Adrenocortical carcinoma cells seem to need glutamine to make nucleotides. Drugs that block glutamine use slowed cancer cells and mouse tumors, and combining one drug with a DNA-damage-response inhibitor worked even better.
Research results
In mice with ACC tumors, JHU-083 reduced tumor growth by more than 80% relative to vehicle after 9 days and prolonged survival. In ACC cells, DON stopped growth at low concentrations (IC50 0.03–4.07 µM). In human ACC serum, 437 metabolites differed from benign tumors, and glutamine was lower. High expression of four glutamine-related nucleotide enzymes was linked to worse survival (relative association; absolute risk not reported).
What this means - more context
This is preclinical and early human metabolomic evidence. The >80% is relative tumor-growth inhibition in mice, not an absolute human survival benefit. No absolute risk increase or decrease for patients was reported. The human data are associations only, so it is not proven that blocking glutamine improves survival in people.
Preclinical and human metabolomic study asking whether adrenocortical carcinoma (ACC) depends on glutamine metabolism and whether glutamine antagonists can suppress tumor growth.
Cross-species multi-omic analysis found conserved glutamine-dependent metabolic rewiring in ACC. Glutamine antagonists DON/JHU-083 inhibited ACC cell viability (IC50 0.03–4.07 µM) and produced >80% relative tumor-growth inhibition after 9 days in a mouse syngeneic implant model, with prolonged survival. The effect was primarily mediated by blocking glutamine-fueled de novo nucleotide biosynthesis and was rescued by nucleosides. DON induced DNA damage and synergized with ATR inhibitor elimusertib. High expression of four glutamine-metabolizing nucleotide enzymes was associated with worse overall survival, and serum metabolomics showed 437 differentially abundant metabolites (FDR<0.05) with depleted circulating glutamine. Absolute human risk reductions were not reported.
Methods Used
Integrated human/mouse ACC RNA-seq, targeted tissue metabolomics in a mouse ACC model, untargeted serum metabolomics in 54 ACC vs 291 age/BMI-matched benign adrenocortical adenoma patients, ACC cell lines, randomized mouse syngeneic/xenograft treatment with JHU-083 vs vehicle, rescue and synergy assays, and TCGA survival analysis.
Main Finding
Glutamine antagonism suppresses ACC growth in preclinical models: >80% relative inhibition of tumor growth after 9 days in mice and IC50 0.03–4.07 µM in ACC cell lines. Mechanistically, DON acts mainly through inhibition of de novo nucleotide biosynthesis, with nucleoside rescue. High expression of PFAS, GMPS, CAD, and CTPS1 was associated with worse overall survival; the absolute survival risk difference was not reported.
Confidence Level
Moderate—robust cross-species preclinical and human metabolomic data support glutamine dependency, but this is not a clinical efficacy study; preprint, no blinding, no metabolic tracing, and absolute human risk/benefit are not reported.
Study Flags
Red Flags
- •Preclinical models with no clinical efficacy endpoints
- •Human serum metabolomics is observational and cannot establish causation
- •No metabolic tracing to directly quantify glutamine fate; no blinding; preprint not peer-reviewed
Surprising Findings
Nucleosides alone completely rescued cancer cells from a glutamine blocker.
Glutamine feeds many pathways; finding that nucleotide rescue fully reverses toxicity suggests nucleotide synthesis is the dominant dependency.
Practical Takeaways
Do not take glutamine-blocking drugs or restrict glutamine based on this study.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 549 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study mixes lab experiments in cells and mice with a comparison of blood samples from people with a rare cancer versus benign tumors. It shows that the cancer cells rely on glutamine and that blocking it shrinks tumors in mice, but it does not prove that the same treatment works or is safe in people.
Strengths
- Cross-species integration of human and mouse transcriptomic and metabolomic data.
- Use of multiple ACC cell lines including a new murine line and human lines with common driver alterations.
- In vivo evaluation in syngeneic and xenograft mouse models with randomized treatment allocation.
Weaknesses
- No randomized controlled trial in humans; clinical efficacy remains unproven.
- No blinding in animal experiments or outcome assessment, increasing risk of performance and detection bias.
- Small sample sizes in some mouse experiments and limited details on randomization methods.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study uses many different methods and checks the same idea in mice and human samples, which makes the lab findings more convincing. But it is not a human clinical trial, so we cannot be sure the treatment will help patients, and the human part only looks at existing samples rather than testing the drug.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
44 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 549 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. The human component is an observational case-control serum metabolomics comparison (ACC vs benign adrenocortical adenomas), not a randomized clinical trial. It cannot establish that glutamine metabolism causes ACC or that glutamine antagonism treats ACC in humans. Preclinical in vitro and mouse in vivo experiments can support mechanistic hypotheses but do not prove human efficacy or safety.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information is disclosed in the provided text; potential author ties to JHU-083 are not explicitly stated.
The provided excerpt lacks a conflict of interest or funding section. JHU-083 is a Johns Hopkins-developed prodrug, which may imply author affiliations or patents, but no disclosure is present in the text.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Gut Feelings cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
35 researchersIf this is your work, this is how we attribute it on Fit Body Science. Vasileios Chortis is listed as the lead author.